Selected research
Industry Research
CD20 Monoclonal Antibodies Industry Research Report 2026
Market perspective
The global CD20 Monoclonal Antibodies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for CD20 Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for CD20 Monoclonal Antibodies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for CD20 Monoclonal Antibodies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of CD20 Monoclonal Antibodies include Chia Tai-Tianqing Pharmaceutical, Innovent Biologics, Shanghai Institute of Biological Products, Shanghai Henlius Biotec, TG Therapeutics, Teva, Roche, Pfizer and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global CD20 Monoclonal Antibodies market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CD20 Monoclonal Antibodies Market by Company
Chia Tai-Tianqing Pharmaceutical
Innovent Biologics
Shanghai Institute of Biological Products
Shanghai Henlius Biotec
TG Therapeutics
Teva
Roche
Pfizer
Novartis
Celltrion
Biogen
Amgen
CD20 Monoclonal Antibodies Segment by Type
Chimeric Antibodies
Humanized Antibodies
Fully Human Antibodies
CD20 Monoclonal Antibodies Segment by Application
Relapsing Multiple Sclerosis
Non-Hodgkin's lymphoma
Leukemia
Other
CD20 Monoclonal Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD20 Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CD20 Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD20 Monoclonal Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of CD20 Monoclonal Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of CD20 Monoclonal Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of CD20 Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chimeric Antibodies
- Humanized Antibodies
- Fully Human Antibodies
Applications
- Relapsing Multiple Sclerosis
- Non-Hodgkin's lymphoma
- Leukemia
- Other
Companies covered
- Chia Tai-Tianqing Pharmaceutical
- Innovent Biologics
- Shanghai Institute of Biological Products
- Shanghai Henlius Biotec
- TG Therapeutics
- Teva
- Roche
- Pfizer
- Novartis
- Celltrion
- Biogen
- Amgen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global CD20 Monoclonal Antibodies Market Size (2021-2032)
- 2.2.2 Global CD20 Monoclonal Antibodies Sales (2021-2032)
- 2.2.3 Global CD20 Monoclonal Antibodies Market Average Price (2021-2032)
- 2.3 CD20 Monoclonal Antibodies by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Chimeric Antibodies
- 2.3.3 Humanized Antibodies
- 2.3.4 Fully Human Antibodies
- 2.4 CD20 Monoclonal Antibodies by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Relapsing Multiple Sclerosis
- 2.4.3 Non-Hodgkin's lymphoma
- 2.4.4 Leukemia
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global CD20 Monoclonal Antibodies Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global CD20 Monoclonal Antibodies Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global CD20 Monoclonal Antibodies Revenue of Manufacturers (2021-2026)
- 3.4 Global CD20 Monoclonal Antibodies Average Price by Manufacturers (2021-2026)
- 3.5 Global CD20 Monoclonal Antibodies Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of CD20 Monoclonal Antibodies, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of CD20 Monoclonal Antibodies, Product Type & Application
- 3.8 Global Manufacturers of CD20 Monoclonal Antibodies, Established Date
- 3.9 Global CD20 Monoclonal Antibodies Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chia Tai-Tianqing Pharmaceutical
- 4.1.1 Chia Tai-Tianqing Pharmaceutical Company Information
- 4.1.2 Chia Tai-Tianqing Pharmaceutical Business Overview
- 4.1.3 Chia Tai-Tianqing Pharmaceutical CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chia Tai-Tianqing Pharmaceutical CD20 Monoclonal Antibodies Product Portfolio
- 4.1.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
- 4.2 Innovent Biologics
- 4.2.1 Innovent Biologics Company Information
- 4.2.2 Innovent Biologics Business Overview
- 4.2.3 Innovent Biologics CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Innovent Biologics CD20 Monoclonal Antibodies Product Portfolio
- 4.2.5 Innovent Biologics Recent Developments
- 4.3 Shanghai Institute of Biological Products
- 4.3.1 Shanghai Institute of Biological Products Company Information
- 4.3.2 Shanghai Institute of Biological Products Business Overview
- 4.3.3 Shanghai Institute of Biological Products CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Institute of Biological Products CD20 Monoclonal Antibodies Product Portfolio
- 4.3.5 Shanghai Institute of Biological Products Recent Developments
- 4.4 Shanghai Henlius Biotec
- 4.4.1 Shanghai Henlius Biotec Company Information
- 4.4.2 Shanghai Henlius Biotec Business Overview
- 4.4.3 Shanghai Henlius Biotec CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shanghai Henlius Biotec CD20 Monoclonal Antibodies Product Portfolio
- 4.4.5 Shanghai Henlius Biotec Recent Developments
- 4.5 TG Therapeutics
- 4.5.1 TG Therapeutics Company Information
- 4.5.2 TG Therapeutics Business Overview
- 4.5.3 TG Therapeutics CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 TG Therapeutics CD20 Monoclonal Antibodies Product Portfolio
- 4.5.5 TG Therapeutics Recent Developments
- 4.6 Teva
- 4.6.1 Teva Company Information
- 4.6.2 Teva Business Overview
- 4.6.3 Teva CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Teva CD20 Monoclonal Antibodies Product Portfolio
- 4.6.5 Teva Recent Developments
- 4.7 Roche
- 4.7.1 Roche Company Information
- 4.7.2 Roche Business Overview
- 4.7.3 Roche CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Roche CD20 Monoclonal Antibodies Product Portfolio
- 4.7.5 Roche Recent Developments
- 4.8 Pfizer
- 4.8.1 Pfizer Company Information
- 4.8.2 Pfizer Business Overview
- 4.8.3 Pfizer CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Pfizer CD20 Monoclonal Antibodies Product Portfolio
- 4.8.5 Pfizer Recent Developments
- 4.9 Novartis
- 4.9.1 Novartis Company Information
- 4.9.2 Novartis Business Overview
- 4.9.3 Novartis CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novartis CD20 Monoclonal Antibodies Product Portfolio
- 4.9.5 Novartis Recent Developments
- 4.10 Celltrion
- 4.10.1 Celltrion Company Information
- 4.10.2 Celltrion Business Overview
- 4.10.3 Celltrion CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Celltrion CD20 Monoclonal Antibodies Product Portfolio
- 4.10.5 Celltrion Recent Developments
- 4.11 Biogen
- 4.11.1 Biogen Company Information
- 4.11.2 Biogen Business Overview
- 4.11.3 Biogen CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Biogen CD20 Monoclonal Antibodies Product Portfolio
- 4.11.5 Biogen Recent Developments
- 4.12 Amgen
- 4.12.1 Amgen Company Information
- 4.12.2 Amgen Business Overview
- 4.12.3 Amgen CD20 Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Amgen CD20 Monoclonal Antibodies Product Portfolio
- 4.12.5 Amgen Recent Developments
5 Global CD20 Monoclonal Antibodies Market Scenario by Region
- 5.1 Global CD20 Monoclonal Antibodies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global CD20 Monoclonal Antibodies Sales by Region: 2021-2032
- 5.2.1 Global CD20 Monoclonal Antibodies Sales by Region: 2021-2026
- 5.2.2 Global CD20 Monoclonal Antibodies Sales by Region: 2027-2032
- 5.3 Global CD20 Monoclonal Antibodies Revenue by Region: 2021-2032
- 5.3.1 Global CD20 Monoclonal Antibodies Revenue by Region: 2021-2026
- 5.3.2 Global CD20 Monoclonal Antibodies Revenue by Region: 2027-2032
- 5.4 North America CD20 Monoclonal Antibodies Market Facts & Figures by Country
- 5.4.1 North America CD20 Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America CD20 Monoclonal Antibodies Sales by Country (2021-2032)
- 5.4.3 North America CD20 Monoclonal Antibodies Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe CD20 Monoclonal Antibodies Market Facts & Figures by Country
- 5.5.1 Europe CD20 Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe CD20 Monoclonal Antibodies Sales by Country (2021-2032)
- 5.5.3 Europe CD20 Monoclonal Antibodies Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific CD20 Monoclonal Antibodies Market Facts & Figures by Country
- 5.6.1 Asia Pacific CD20 Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific CD20 Monoclonal Antibodies Sales by Country (2021-2032)
- 5.6.3 Asia Pacific CD20 Monoclonal Antibodies Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America CD20 Monoclonal Antibodies Market Facts & Figures by Country
- 5.7.1 South America CD20 Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America CD20 Monoclonal Antibodies Sales by Country (2021-2032)
- 5.7.3 South America CD20 Monoclonal Antibodies Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa CD20 Monoclonal Antibodies Market Facts & Figures by Country
- 5.8.1 Middle East and Africa CD20 Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa CD20 Monoclonal Antibodies Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa CD20 Monoclonal Antibodies Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global CD20 Monoclonal Antibodies Sales by Type (2021-2032)
- 6.1.1 Global CD20 Monoclonal Antibodies Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global CD20 Monoclonal Antibodies Sales Market Share by Type (2021-2032)
- 6.2 Global CD20 Monoclonal Antibodies Revenue by Type (2021-2032)
- 6.2.1 Global CD20 Monoclonal Antibodies Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global CD20 Monoclonal Antibodies Revenue Market Share by Type (2021-2032)
- 6.3 Global CD20 Monoclonal Antibodies Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global CD20 Monoclonal Antibodies Sales by Application (2021-2032)
- 7.1.1 Global CD20 Monoclonal Antibodies Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global CD20 Monoclonal Antibodies Sales Market Share by Application (2021-2032)
- 7.2 Global CD20 Monoclonal Antibodies Revenue by Application (2021-2032)
- 7.2.1 Global CD20 Monoclonal Antibodies Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global CD20 Monoclonal Antibodies Revenue Market Share by Application (2021-2032)
- 7.3 Global CD20 Monoclonal Antibodies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 CD20 Monoclonal Antibodies Value Chain Analysis
- 8.1.1 CD20 Monoclonal Antibodies Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 CD20 Monoclonal Antibodies Production Mode & Process
- 8.2 CD20 Monoclonal Antibodies Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 CD20 Monoclonal Antibodies Distributors
- 8.2.3 CD20 Monoclonal Antibodies Customers
9 Global CD20 Monoclonal Antibodies Analyzing Market Dynamics
- 9.1 CD20 Monoclonal Antibodies Industry Trends
- 9.2 CD20 Monoclonal Antibodies Industry Drivers
- 9.3 CD20 Monoclonal Antibodies Industry Opportunities and Challenges
- 9.4 CD20 Monoclonal Antibodies Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst